Crystal Adam 4

What Happened
Crystal Adam, President of R&D at Tango Therapeutics (TNGX), sold 20,251 shares on March 5, 2026, at $15.00 per share for gross proceeds of $303,765. This was a sale (not a purchase or option exercise) and therefore is generally a routine disposition rather than a direct bullish signal.

Key Details

• Transaction date and price: March 5, 2026 — 20,251 shares sold at $15.00 each (total ≈ $303,765).
• Filing date: Form 4 filed March 9, 2026 (reports the March 5, 2026 transaction).
• Shares owned after transaction: Not specified in the information provided here; see the full Form 4 for beneficial ownership totals.
• Footnote: The filing states the trades were effected pursuant to a Rule 10b5-1 trading plan adopted October 27, 2025. (F1)
• Timeliness: No late-filing flag provided here; Form 4s are typically due within two business days of the transaction—check the filing for any "L" flag if timeliness is a concern.

Context
A Rule 10b5-1 plan indicates the sale was pre-scheduled and executed under a written plan, which commonly reduces the likelihood the trade was made based on material nonpublic information. Sales by insiders are often routine (for diversification, liquidity, or tax planning); purchases are typically considered more informative about insider sentiment. Always review the full Form 4 for additional details and combine insider activity with other research before making investment decisions.